"Dosing the first patient in Phase III represents a major milestone for MDR-001 and for AI-enabled drug development," said Zhangming Niu, Founder and Chief Executive Officer of MindRank. "We believe ...

Partnership to use Chemify’s programmable chemistry technology and Sanacor’s translational biology expertise to accelerate ...

Immunotherapy has revolutionized cancer treatment, with immune checkpoint inhibitors (ICIs) playing a pivotal role. However, current ICIs, primarily monoclonal antibodies, face significant challenges ...

Boehringer Ingelheim acquires an exclusive license for a preclinical oral immunology program from Sitryx in a deal worth over ...

Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.

Researchers have discovered a promising new approach to lung cancer treatment. A small molecule called AVJ16 selectively blocks the cancer-driving protein IGF2BP1, halting tumor growth in preclinical ...

Small Molecule Drug Development Core Facility (SMDD Core) has the automation equipment, libraries, and experienced personnel to support a wide range of assay ...

Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital ...